235 related articles for article (PubMed ID: 18578857)
1. ELR+ CXC chemokine expression in benign and malignant colorectal conditions.
Rubie C; Frick VO; Wagner M; Schuld J; Gräber S; Brittner B; Bohle RM; Schilling MK
BMC Cancer; 2008 Jun; 8():178. PubMed ID: 18578857
[TBL] [Abstract][Full Text] [Related]
2. Changes in CXCL12/CXCR4-chemokine expression during onset of colorectal malignancies.
Oliveira Frick V; Rubie C; Ghadjar P; Faust SK; Wagner M; Gräber S; Schilling MK
Tumour Biol; 2011 Feb; 32(1):189-96. PubMed ID: 20865359
[TBL] [Abstract][Full Text] [Related]
3. Differential CXC receptor expression in colorectal carcinomas.
Rubie C; Kollmar O; Frick VO; Wagner M; Brittner B; Gräber S; Schilling MK
Scand J Immunol; 2008 Dec; 68(6):635-44. PubMed ID: 18959627
[TBL] [Abstract][Full Text] [Related]
4. CCR6/CCL20 chemokine expression profile in distinct colorectal malignancies.
Frick VO; Rubie C; Kölsch K; Wagner M; Ghadjar P; Graeber S; Glanemann M
Scand J Immunol; 2013 Sep; 78(3):298-305. PubMed ID: 23790181
[TBL] [Abstract][Full Text] [Related]
5. Chemokine expression in hepatocellular carcinoma versus colorectal liver metastases.
Rubie C; Frick VO; Wagner M; Weber C; Kruse B; Kempf K; König J; Rau B; Schilling M
World J Gastroenterol; 2006 Nov; 12(41):6627-33. PubMed ID: 17075975
[TBL] [Abstract][Full Text] [Related]
6. Correlation of IL-8 with induction, progression and metastatic potential of colorectal cancer.
Rubie C; Frick VO; Pfeil S; Wagner M; Kollmar O; Kopp B; Graber S; Rau BM; Schilling MK
World J Gastroenterol; 2007 Oct; 13(37):4996-5002. PubMed ID: 17854143
[TBL] [Abstract][Full Text] [Related]
7. Identification of an intermediate signature that marks the initial phases of the colorectal adenoma-carcinoma transition.
Tang H; Guo Q; Zhang C; Zhu J; Yang H; Zou YL; Yan Y; Hong D; Sou T; Yan XM
Int J Mol Med; 2010 Nov; 26(5):631-41. PubMed ID: 20878084
[TBL] [Abstract][Full Text] [Related]
8. Expression and gene polymorphisms of the chemokine CXCL5 in colorectal cancer patients.
Dimberg J; Dienus O; Löfgren S; Hugander A; Wågsäter D
Int J Oncol; 2007 Jul; 31(1):97-102. PubMed ID: 17549409
[TBL] [Abstract][Full Text] [Related]
9. The Clinicopathological Significance of the CXCR2 Ligands, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, and CXCL8 in Gastric Cancer.
Yamamoto Y; Kuroda K; Sera T; Sugimoto A; Kushiyama S; Nishimura S; Togano S; Okuno T; Yoshii M; Tamura T; Toyokawa T; Tanaka H; Muguruma K; Ohira M; Yashiro M
Anticancer Res; 2019 Dec; 39(12):6645-6652. PubMed ID: 31810929
[TBL] [Abstract][Full Text] [Related]
10. Up-regulation of CXC chemokines and their receptors: implications for proinflammatory microenvironments of ovarian carcinomas and endometriosis.
Furuya M; Suyama T; Usui H; Kasuya Y; Nishiyama M; Tanaka N; Ishiwata I; Nagai Y; Shozu M; Kimura S
Hum Pathol; 2007 Nov; 38(11):1676-87. PubMed ID: 17707463
[TBL] [Abstract][Full Text] [Related]
11. Involvement of chemokine receptor CCR6 in colorectal cancer metastasis.
Rubie C; Oliveira V; Kempf K; Wagner M; Tilton B; Rau B; Kruse B; Konig J; Schilling M
Tumour Biol; 2006; 27(3):166-74. PubMed ID: 16641550
[TBL] [Abstract][Full Text] [Related]
12. CXCL5, a promoter of cell proliferation, migration and invasion, is a novel serum prognostic marker in patients with colorectal cancer.
Kawamura M; Toiyama Y; Tanaka K; Saigusa S; Okugawa Y; Hiro J; Uchida K; Mohri Y; Inoue Y; Kusunoki M
Eur J Cancer; 2012 Sep; 48(14):2244-51. PubMed ID: 22197219
[TBL] [Abstract][Full Text] [Related]
13. Reduced expression of microenvironmental Th1 cytokines accompanies adenomas-carcinomas sequence of colorectum.
Cui G; Goll R; Olsen T; Steigen SE; Husebekk A; Vonen B; Florholmen J
Cancer Immunol Immunother; 2007 Jul; 56(7):985-95. PubMed ID: 17160410
[TBL] [Abstract][Full Text] [Related]
14. Enhanced ENA-78 and IL-8 expression in patients with malignant pancreatic diseases.
Frick VO; Rubie C; Wagner M; Graeber S; Grimm H; Kopp B; Rau BM; Schilling MK
Pancreatology; 2008; 8(4-5):488-97. PubMed ID: 18765953
[TBL] [Abstract][Full Text] [Related]
15. MMP3 and CXCL1 are potent stromal protein markers of dysplasia-carcinoma transition in sporadic colorectal cancer.
Sipos F; Germann TM; Wichmann B; Galamb O; Spisák S; Krenács T; Tulassay Z; Molnár B; Műzes G
Eur J Cancer Prev; 2014 Sep; 23(5):336-43. PubMed ID: 24999605
[TBL] [Abstract][Full Text] [Related]
16. Tissue and serum galectin-1 expression in patients with colorectal carcinoma.
Sheng TH; Rong LX; Li ZY; Bo J; Lei S
Hepatogastroenterology; 2012; 59(114):389-94. PubMed ID: 22353504
[TBL] [Abstract][Full Text] [Related]
17. IL-17A in the tumor microenvironment of the human colorectal adenoma-carcinoma sequence.
Cui G; Yuan A; Goll R; Florholmen J
Scand J Gastroenterol; 2012 Nov; 47(11):1304-12. PubMed ID: 22989213
[TBL] [Abstract][Full Text] [Related]
18. CXC chemokines located in the 4q21 region are up-regulated in breast cancer.
Bièche I; Chavey C; Andrieu C; Busson M; Vacher S; Le Corre L; Guinebretière JM; Burlinchon S; Lidereau R; Lazennec G
Endocr Relat Cancer; 2007 Dec; 14(4):1039-52. PubMed ID: 18045955
[TBL] [Abstract][Full Text] [Related]
19. Characterization of contraction-inducible CXC chemokines and their roles in C2C12 myocytes.
Nedachi T; Hatakeyama H; Kono T; Sato M; Kanzaki M
Am J Physiol Endocrinol Metab; 2009 Oct; 297(4):E866-78. PubMed ID: 19622786
[TBL] [Abstract][Full Text] [Related]
20. Role of MEK1 and DIAPH3 expression in colorectal adenoma-carcinoma sequence.
Foda AAM; El-Hawary AK; Elnaghi K; Eldehna WM; Enan ET
Tumour Biol; 2024; 46(1):1-11. PubMed ID: 38728194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
